Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 10,663

Document Document Title
WO/2010/125831A1
The present invention relates to sulfamoyl benzoic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment...  
WO/2010/126607A3
Efficient method for preparing the enone intermediate (VII) used in the synthesis of tetracyclines derivatives. In particular, the invention provides a synthesis which allows for substituents at positions 4a, 5, 5a, and 12a of the tetrac...  
WO/2010/123956A2
Provided herein are 2,5-disubstituted arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or ...  
WO/2010/123956A3
Provided herein are 2,5-disubstituted arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or ...  
WO/2010/123139A1
Disclosed is a long-chain fatty acid elongase (Elovl6) inhibitor, which is characterized by comprising at least one of a compound represented by formula (I), a pharmaceutically acceptable salt of the compound, and a solvate of the compou...  
WO/2010/123071A1
Disclosed is a dye composition which has high clarity and color developability, while exhibiting excellent fastnesses such as heat resistance, wet heat resistance and water resistance. Specifically disclosed are a triarylmethane compound...  
WO/2010/122968A1
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...  
WO/2010/120370A3
Gamma-amino-butyric acid derivatives of formula (I) that are GABAB receptor ligands, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives and pharmaceutical compositions thereof for treating dise...  
WO/2010/115952A1
The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a p...  
WO/2010/116142A3
The invention provides fluorophores of formulae (I) and (II) and also fluorescent sensor compounds comprising fluorophore moieties based on such fluorophores in combination with a receptor moiety. There is further provided a method of se...  
WO/2010/116142A2
The invention provides fluorophores of formulae (I) and (II) and also fluorescent sensor compounds comprising fluorophore moieties based on such fluorophores in combination with a receptor moiety. There is further provided a method of se...  
WO/2010/113492A1
Provided is a method that can safely manufacture a fluorine-containing N-alkyl sulfonyl imide compound, with high yield, by alkylating either a fluorine-containing sulfonyl imide acid or a fluorine-containing sulfonyl imidate using eithe...  
WO/2010/113458A1
Disclosed is a commercially advantageous method for manufacturing a 1,5-benzodiazepine compound. A compound (5) is obtained from a reaction formula and used as an intermediate.  
WO2010110484A1
Provided is an onium salt represented by formula (1): Q+·(R4SO2)2N-. [In formula (1), Q+ is a quaternary ammonium cation represented by formula (2) (wherein R1 represents a C1-6 alkyl group, R2 represents a hydrogen atom or a C1-4 alkyl...  
WO/2010/078449A3
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...  
WO/2010/106364A2
The present invention relates to a process for hydrogenating a substrate comprising a carbon- heteroatom double bond, the process comprising the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst...  
WO/2010/106364A3
The present invention relates to a process for hydrogenating a substrate comprising a carbon- heteroatom double bond, the process comprising the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst...  
WO/2010/107384A1
A compound of formula (I) N-oxides, addition salts, quaternary amines metal complexes stereochemically isomeric forms and metabolites thereof, wherein A is CR1 Or N; formula (A) or formula (B) D is H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkyn...  
WO/2010/102154A3
The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin. The compounds provided include those of the general fo...  
WO/2010/100413A3
The invention provides a functionalised compound which is a sulfonylhydrazone compound of formula (XXXa) wherein n is an integer equal to or greater than 3; L is a single bond or a linker group of formula (XII) as defined herein, R and R...  
WO/2010/102154A2
The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin. The compounds provided include those of the general fo...  
WO/2010/097811A1
The present invention provides a process for the preparation of some novel 2-aryl and 2,2-diaryl aldehydes and analogues which are privileged intermediates for commercially important nonsteroidal anti-inflammatory drugs including naproxe...  
WO/2010/097811A4
The present invention provides a process for the preparation of some novel 2-aryl and 2,2-diaryl aldehydes and analogues which are privileged intermediates for commercially important nonsteroidal anti-inflammatory drugs including naproxe...  
WO/2010/092098A1
The present invention relates to a method for producing compounds of general formula (I), in which m, n, R1, and R2 are defined as described below, to enantiomers thereof, to diastereomers thereof, to mixtures thereof, and to salts there...  
WO/2010/091543A1
The present invention relates to novel hydrazino-cyclobut-3-ene-1,2-dione compounds of Formula (I) as selective CXCR2 antagonists, pharmaceutical compositions containing the novel compounds, as well as methods for treating or preventing ...  
WO/2010/092180A1
The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of s...  
WO/2010/086878A3
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta. Further, the present invention relates to processes of prepari...  
WO/2010/083442A1
Disclosed are compounds of Formula (1), in which A1, Z1, Z1A, Z2, Z2A, L1 and Z3 are as defined in the claims, which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and their use in treating d...  
WO/2010/076033A1
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspe...  
WO/2010/075869A1
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)- mediated transcription and signaling under hypoxic conditions. In one asp...  
WO/2010/076033A9
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspe...  
WO/2010/078449A2
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...  
WO/2010/072831A1
An oligonucleotide which comprises at least one internucleotide linkage comprising a P-S-R bond and at least two nucleosides, wherein R corresponds to the formula (I) wherein A is a geminally substituted alkylene group, preferably CH2, X...  
WO/2010/072734A2
Provided herein are compounds, compositions and methods for preventing or treating gastrointestinal cancer in a mammal, wherein the method comprises delivering an effective amount of a COX-2 or a similar sulfonamide inhibitor as a prodru...  
WO/2010/074062A1
Aminoethanol is reacted with a fluoroalkylsulfonic anhydride to obtain a fluoroalkylsulfonylaminoethanol (first step: sulfonylamidation step). The fluoroalkylsulfonylaminoethanol is esterified with an α-substituted acrylate derivative t...  
WO/2010/072734A3
Provided herein are compounds of formula (I) as well as compounds of formula (I) which are prodrugs in which the (R7)a-phenyl-S(O)2NH group represents a sulphonamide-bond compound, compositions and methods for preventing or treating gast...  
WO/2010/070615A1
Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2...  
WO/2010/070076A1
The invention related to alkanoic acid derivatives of Formula (IIa) and (IIb). These compounds of the invention were found to have activity as HDAC inhibitors.  
WO/2010/066847A1
The present invention concerns novel substituted aryl derivatives, their process of preparation and their use for inhibiting virus replication and for treating viral diseases or disorders such as HIV and/or HCV infection.  
WO/2010/057865A1
A compound of formula (I) and salts thereof are provided: Wherein n and R1 are defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a dise...  
WO/2010/056527A2
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the co...  
WO/2010/055005A1
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates...  
WO/2010/056527A3
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the co...  
WO/2010/055887A1
A novel β-(trifluoromethyl)vinyldiaryl sulfonium salt represented by general formula (I), which can be used for simple syntheses of various useful compounds each containing a trifluoromethyl group, or the like. (In formula (I), R1 and R...  
WO/2010/051933A3
The present invention relates to substituted sulphonamido phenoxybenzamide compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined in the claims, to pharmaceutical compositions and combinations co...  
WO/2010/051933A2
The present invention relates to substituted sulphonamido phenoxybenzamide compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined in the claims, to pharmaceutical compositions and combinations co...  
WO/2010/049946A2
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes ...  
WO/2010/049946A3
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes ...  
WO/2010/048332A2
Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.  
WO/2010/048332A3
Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.  

Matches 401 - 450 out of 10,663